Cereno Scientific to Host Capital Markets Day on February 5, 2026

The Capital Markets Day will provide investors, analysts, and financial media with an update on Cereno Scientific's clinical development programs, [MR1]strategic priorities, and growth ambitions. The program will feature presentations by members of Cereno Scientific's management team, as well as contributions from external speakers with relevant scientific and clinical expertise.

The program will focus on Cereno Scientific's lead candidate CS1, which is being developed as a disease-modifying treatment for pulmonary arterial hypertension (PAH). CS1 has been granted Orphan Drug Designation (ODD) in both the U.S. and Europe and earlier this year received Fast Track designation from the U.S. Food and Drug Administration (FDA), underscoring its potential to address a serious disease with high unmet medical need. The company recently received regulatory clearance from the FDA for its planned Phase IIb trial of CS1, with patient recruitment expected to commence in Q2 2026. The event will also offer deeper insights into the significant unmet medical needs within the disease, as well as the scientific rationale underpinning its pioneering therapeutic approach based on epigenetic modulation through histone deacetylase inhibition (HDACi), with the potential to modify the underlying drivers of disease rather than solely addressing symptoms.

Further details regarding the agenda, speakers, venue, and registration will be communicated closer to the event.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function and patient quality of life, consistent with reverse vascular remodeling. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, a new chemical entity with disease-modifying potential, showed favorable safety and tolerability profile in a Phase I trial. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.